Catalyst Pharmaceutical
CPRX
CPRX was delisted on the 14th of July, 2026.
87 hedge funds and large institutions have $180M invested in Catalyst Pharmaceutical in 2015 Q2 according to their latest regulatory filings, with 35 funds opening new positions, 24 increasing their positions, 18 reducing their positions, and 14 closing their positions.
684% more call options, than puts
Call options by funds: $588K | Put options by funds: $75K
150% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 14
33% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 18
32% more funds holding
Funds holding: 66 → 87 (+21)
7% more capital invested
Capital invested by funds: $168M → $180M (+$11.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$10.3M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$7.14M |
| 3 |
CCM
Consonance Capital Management
New York
|
+$2.66M |
| 4 |
State Street
Boston,
Massachusetts
|
+$2.46M |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$2.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$12.4M |
| 2 |
Morgan Stanley
New York
|
-$1.6M |
| 3 |
PA
Perceptive Advisors
New York
|
-$1.39M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.26M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
-$916K |
CPRX Hedge Fund Activity: Q2 2015 in Review
87 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q2 2015, worth a combined $180M — up 6.7% from $168M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new CPRX positions and 14 closed out — a net gain of 21 holders — while 24 added to existing stakes and 18 trimmed.
The largest buyer was Federated Hermes, adding an estimated $10.3M. The largest seller was Point72 Asset Management, cutting an estimated $12.4M.
- 87 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q2 2015, up from 66 in Q1 2015.
- Funds reported $180M of Catalyst Pharmaceutical stock for Q2 2015, up 6.7% quarter-over-quarter.
- 35 funds opened new Catalyst Pharmaceutical positions in Q2 2015 and 14 closed out, a net change of +21 holders.
- The largest Catalyst Pharmaceutical buyer in Q2 2015 was Federated Hermes, an estimated $10.3M added.
- The largest Catalyst Pharmaceutical seller in Q2 2015 was Point72 Asset Management, an estimated $12.4M sold.
Based on aggregated 13F filings for Q2 2015.